Oxidative Modification of Brain Proteins in Alzheimer's Disease: Perspective on Future Studies Based on Results of Redox Proteomics Studies

2012 ◽  
Vol 33 (s1) ◽  
pp. S243-S251 ◽  
Author(s):  
Rukhsana Sultana ◽  
D. Allan Butterfield
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Oxidative Modification ◽  
Redox Proteomics ◽  
Brain Proteins ◽  
Future Studies

Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: A redox proteomics analysis

2006 ◽  
Vol 27 (7) ◽  
pp. 918-925 ◽  
Author(s):  
Rukhsana Sultana ◽  
Debra Boyd-Kimball ◽  
H. Fai Poon ◽  
Jain Cai ◽  
William M. Pierce ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Oxidative Modification ◽  
Down Regulation ◽  
Proteomics Analysis ◽  
Redox Proteomics

Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: An initial assessment

2006 ◽  
Vol 10 (4) ◽  
pp. 391-397 ◽  
Author(s):  
D. Allan Butterfield ◽  
Anastazija Gnjec ◽  
H. Fai Poon ◽  
Alessandra Castegna ◽  
William M. Pierce ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Initial Assessment ◽  
Redox Proteomics ◽  
Brain Proteins ◽  
Oxidatively Modified

scholarly journals Plasma Neurofilament Light and Future Declines in Cognition and Function in Alzheimer’s Disease in the FIT-AD Trial

2021 ◽  
pp. 1-11
Author(s):  
Danni Li ◽  
Lin Zhang ◽  
Nathaniel W. Nelson ◽  
Michelle M. Mielke ◽  
Fang Yu
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Daily Living ◽  
Short Term ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
Linear Mixed Effects ◽  
Future Studies ◽  
Rate Of Decline ◽  
And Function

Background: Utilities of blood-based biomarkers in Alzheimer’s disease (AD) clinical trials remain unknown. Objective: To evaluate the ability of plasma neurofilament light chain (NfL) to predict future declines in cognition and activities of daily living (ADL) outcomes in 26 older adults with mild-to-moderate AD dementia from the FIT-AD Trial. Methods: Plasma NfL was measured at baseline and 3 and 6 months. Cognition and ADL were assessed using the AD Assessment Scale-Cognition (ADAS-Cog) and AD Uniform Dataset Instruments and Disability Assessment for Dementia (DAD), respectively, at baseline, 3, 6, 9, and 12 months. Linear mixed effects models were used to examine the associations between baseline or change in plasma NfL and changes in outcomes. Results: Higher baseline plasma NfL was associated with greater rate of decline in ADAS-Cog from baseline to 6 months (standardized estimate of 0.00462, p = 0.02853) and in ADL from baseline to 12 months (standardized estimate of –0.00284, p = 0.03338). Greater increase in plasma NfL in short term from baseline to 3 months was associated with greater rate of decline in memory and ADL from 3 to 6 months (standardized estimate of –0.04638 [0.003], p = 0.01635; standardized estimate of –0.03818, p = 0.0435) and greater rate of decline in ADL from 3 to 12 month (standardized estimate of –0.01492, p = 0.01082). Conclusion: This study demonstrated that plasma NfL might have the potential to predict cognitive and function decline up to 12 months. However, future studies with bigger sample sizes need to confirm the findings.

scholarly journals Proteome analysis of brain proteins in Alzheimer's disease: Subproteomics following sequentially extracted protein preparation

2004 ◽  
Vol 6 (3) ◽  
pp. 257-268 ◽  
Author(s):  
Aiko Shiozaki ◽  
Teruyuki Tsuji ◽  
Ryuichi Kohno ◽  
Jun Kawamata ◽  
Kengo Uemura ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Proteome Analysis ◽  
Protein Preparation ◽  
Brain Proteins

scholarly journals Proteomic identification of nitrated brain proteins in early Alzheimer’s disease inferior parietal lobule

2008 ◽  
Vol 13 (8b) ◽  
pp. 2019-2029 ◽  
Author(s):  
Tanea T. Reed ◽  
William M. Pierce Jr. ◽  
Delano M. Turner ◽  
William R. Markesbery ◽  
D. Allan Butterfield
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Inferior Parietal Lobule ◽  
Brain Proteins ◽  
Proteomic Identification ◽  
Parietal Lobule ◽  
Early Alzheimer’S Disease

Diagnostic utility of sound naming in early Alzheimer’s disease

2009 ◽  
Vol 15 (2) ◽  
pp. 231-238 ◽  
Author(s):  
HYEON-AE JEON ◽  
KYOUNG-MIN LEE
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Picture Naming ◽  
Temporal Cortex ◽  
Cognitive Domain ◽  
Diagnostic Utility ◽  
Future Studies ◽  
Early Alzheimer’S Disease

AbstractWhile it is well known that picture naming (PN) is impaired in Alzheimer’s disease (AD), sound naming (SN) has not been thoroughly investigated. We postulated that SN might be impaired more severely and earlier than PN, given the early involvement of the temporal cortex by AD-related pathology. SN and PN were assessed in 21 normal participants, 40 patients with mild cognitive impairment (MCI), and 27 patients in early stages of AD. Our results showed that SN accuracy and latency were more sensitive to advancing pathology in AD than PN accuracy and latency. SN was more useful and specific in distinguishing MCI patients from normal participants and therefore in potentially identifying the subset of MCI patients who already have impairment in more than one cognitive domain and may actually have incipient AD. These findings indicate a potential diagnostic utility of SN for early detection of the disease. Furthermore, even though most AD patients demonstrated more or less comparable impairment in both tasks, some were disproportionately impaired on SN and others were differentially impaired on PN. Future studies may be able to show that these discrepant groups correspond to patients with right and left hemisphere predominant AD, respectively. (JINS, 2009, 15, 231–238.)

Sign in / Sign up

Export Citation Format

Share Document